$6.70 $0.12 (1.8%)

04:00 PM EDT on 10/17/19

Viking Therapeutics (NASDAQ:VKTX)

CAPS Rating: 3 out of 5

Current Price $6.70 Mkt Cap $602.9M
Open $6.61 P/E Ratio 0.00
Prev. Close $6.58 Div. (Yield) $0.00 (0.0%)
Daily Range $6.57 - $6.74 Volume 670,609
52-Wk Range $6.15 - $11.03 Avg. Daily Vol.

Caps

How do you think NASDAQ:VKTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

52 Outperform
6 Underperform
 

All-Star Players

21 Outperform
4 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:VKTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

usubanas (99.51)
Submitted December 07, 2017

Can go up easily 10X if good results in NASH. Same MOA as MDGL.

Jordrok (83.11)
Submitted May 05, 2018

No revenues yet...

NASDAQ:VKTX VS S&P 500 (SPY)

NASDAQ:VKTX Summary

Fools bullish on NASDAQ:VKTX are also bullish on:

Fools bearish on NASDAQ:VKTX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about VKTX.

Recs

0
Member Avatar ak1010 (99.82) Submitted: 10/11/2018 10:33:42 AM : Outperform Start Price: $14.00 NASDAQ:VKTX Score: -60.04

Dan

Recs

0
Member Avatar Bigsef77 (66.78) Submitted: 9/18/2018 10:33:58 AM : Outperform Start Price: $5.26 NASDAQ:VKTX Score: +17.98

Why Viking Therapeutics Stock Is Soaring Today
Motley Fool
George Budwell, The Motley Fool
,Motley Fool•September 18, 2018
What happened
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech, saw its shares rise by as much as 180% in premarket trading today. The spark?

Viking's shares are soaring in response to a positive mid-stage result for its experimental nonalcoholic steatohepatitis (NASH) medicine VK2809. Most critically, the drug seems to compare favorably to Madrigal Pharmaceuticals' (NASDAQ: MDGL) MGL-3196 in terms of both safety and efficacy.

As a reminder, Madrigal's shares exploded higher earlier this year after reporting mid-stage results for MGL-3196. So, not surprisingly, Madrigal's shares sank by a staggering 14% in pre-market trading on the news that a major rival might have a more potent drug in development.

Recs

0
Member Avatar rthr0 (48.92) Submitted: 9/6/2018 6:29:16 PM : Outperform Start Price: $11.68 NASDAQ:VKTX Score: -46.87

new drugs and emerging NASH market

Leaderboard

Find the members with the highest scoring picks in VKTX.

Score Leader

skyrocket29

skyrocket29 (52.88) Score: +456.18

The Score Leader is the player with the highest score across all their picks in VKTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Under5 < 20 7/27/2017 Outperform 5Y $1.12 +498.21% +20.64% +477.58 3 Comments
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. skyrocket29 52.88 7/24/2017 Outperform 1Y $1.16 +477.59% +21.41% +456.18 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. usubanas 99.51 12/7/2017 Outperform 5Y $2.85 +135.09% +13.70% +121.39 4 Comments
anchak 99.92 9/18/2018 Underperform NS $19.09 -64.90% +2.75% +67.65 0 Comment
usubanas2 91.93 12/12/2017 Outperform 5Y $3.87 +73.35% +11.92% +61.43 0 Comment
stainsolution < 20 1/2/2018 Outperform 5Y $4.09 +63.81% +11.68% +52.13 0 Comment
TMFGBudwell < 20 5/4/2018 Outperform 5Y $4.13 +62.23% +14.38% +47.85 0 Comment
efarev 97.72 1/3/2018 Outperform 5Y $4.51 +48.56% +10.87% +37.69 0 Comment
portefeuille3 96.81 5/18/2018 Outperform 5Y $5.18 +29.34% +10.18% +19.17 0 Comment
odocoileus < 20 5/18/2018 Outperform 5Y $5.21 +28.60% +10.14% +18.45 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VKTX.